Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Cuzick

Showing results (131-140 of 421) with videos related to

Pageof 43
Sort By:
JAMA Oncology|April 6, 2018
Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast DensityAdam R Brentnall, Jack Cuzick, Diana S M Buist, et al.
Breast Cancer Research and Treatment|May 17, 2012
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancerIvana Sestak, Michelle Harvie, Anthony Howell, et al.
Vaccine|December 4, 2012
Nucleic acid tests for the detection of alpha human papillomavirusesMario Poljak, Jack Cuzick, Boštjan J Kocjan, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|February 1, 2003
Psychological impact of colorectal cancer screeningJane Wardle, Sara Williamson, Stephen Sutton, et al.
Cancer Medicine|March 12, 2021
Consistency of the S5 DNA methylation classifier in formalin-fixed biopsies versus corresponding exfoliated cells for the detection of pre-cancerous cervical lesionsCaroline Reuter, Matthew Preece, Rawinder Banwait, et al.
The Lancet. Oncology|December 18, 2007
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial, John F Forbes, Jack Cuzick, et al.
Bone|April 28, 2019
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopeniaIvana Sestak, Glen M Blake, Rajesh Patel, et al.
Public Health Genomics|July 12, 2016
Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative InvestigationSamuel G Smith, Lucy Side, Susanne F Meisel, et al.
Lancet (London, England)|July 18, 2003
Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trialJoan Houghton, W D George, Jack Cuzick, et al.
Cancer|June 29, 2006
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trialAman U Buzdar, Jean-Paul Guastalla, Jean-Marc Nabholtz, et al.
Pageof 43

Showing results (131-140 of 421) with videos related to

Sort By:
Pageof 43
JAMA Oncology|April 6, 2018
Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast DensityAdam R Brentnall, Jack Cuzick, Diana S M Buist, et al.
Breast Cancer Research and Treatment|May 17, 2012
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancerIvana Sestak, Michelle Harvie, Anthony Howell, et al.
Vaccine|December 4, 2012
Nucleic acid tests for the detection of alpha human papillomavirusesMario Poljak, Jack Cuzick, Boštjan J Kocjan, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|February 1, 2003
Psychological impact of colorectal cancer screeningJane Wardle, Sara Williamson, Stephen Sutton, et al.
Cancer Medicine|March 12, 2021
Consistency of the S5 DNA methylation classifier in formalin-fixed biopsies versus corresponding exfoliated cells for the detection of pre-cancerous cervical lesionsCaroline Reuter, Matthew Preece, Rawinder Banwait, et al.
The Lancet. Oncology|December 18, 2007
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial, John F Forbes, Jack Cuzick, et al.
Bone|April 28, 2019
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopeniaIvana Sestak, Glen M Blake, Rajesh Patel, et al.
Public Health Genomics|July 12, 2016
Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative InvestigationSamuel G Smith, Lucy Side, Susanne F Meisel, et al.
Lancet (London, England)|July 18, 2003
Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trialJoan Houghton, W D George, Jack Cuzick, et al.
Cancer|June 29, 2006
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trialAman U Buzdar, Jean-Paul Guastalla, Jean-Marc Nabholtz, et al.
Pageof 43